A dynamic force in the fight against infectious diseases

Committed to protecting the world against dangerous and difficult-to-treat fungal pathogens.

Learn More

A ground-breaking advancement

Fungerps: our novel anti-fungal agents

The fungerps are an innovative new weapon for potential deployment against a range of serious fungal infections.

Learn More

Innovation in action

Life-Threatening Infections

We’re bringing new weapons to the fight against debilitating and life-threatening infections that pose serious challenges in hospitals.

Learn More

Serving Unmet Needs

Anti-microbial resistance threat

The increase of antifungal-resistant pathogens is reported globally. Considering the limited treatment options and often deadly outcomes of these diseases, antifungal resistance is a significant global health threat.

Learn More

Our pipeline

Our work on meaningful scientific breakthroughs has the power to change lives.

Learn More

Latest news

  • 11/13/23

    SCYNEXIS Reports Third Quarter 2023 Financial Results and Provides Corporate Update

    Read More >
  • 10/24/23

    SCYNEXIS Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM)

    Read More >
  • 10/16/23

    SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology (TIMM) October 20-23 in Athens, Greece

    Read More >
  • 09/28/23

    SCYNEXIS Issues a Voluntary Nationwide Recall of BREXAFEMME® (ibrexafungerp tablets) due to potential for cross contamination with a non-antibacterial ß-lactam drug substance

    Read More >
  • 08/28/23

    SCYNEXIS to Participate in September Investor Conferences

    Read More >
  • 08/14/23

    SCYNEXIS Reports Second Quarter 2023 Financial Results and Provides Corporate Update

    Read More >
  • 07/20/23

    SCYNEXIS and Hansoh Pharma Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China

    Read More >
  • 06/21/23

    SCYNEXIS Announces Achievement of First Development Milestone of $25 Million Under Exclusive License Agreement with GSK

    Read More >
  • 06/15/23

    SCYNEXIS to Participate in the Maxim Group Virtual Healthcare Conference

    Read More >
  • 05/12/23

    SCYNEXIS Reports Closing of Exclusive License Agreement with GSK for BREXAFEMME® (Ibrexafungerp Tablets)

    Read More >

View All

Interested in learning more about our products, partnership opportunities and more?

Learn More

Make a Difference

Join Our Team

Our people are on a mission to cure infectious diseases and make a real difference in the lives of people around the world. Are you up for the challenge? Discover why you should join SCYNEXIS in the fight against fungal disease.

Learn More